Systematic Review: microRNAs as Potential Biomarkers in Mild Cognitive Impairment Diagnosis

Autores
Ogonowski, Natalia Soledad; Salcidua, Stefanny; Leon, Tomas; Chamorro Veloso, Nayaret; Valls, Cristian; Avalos, Constanza; Bisquertt, Alejandro; Rentería, Miguel E.; Orellana, Paulina; Duran Aniotz, Claudia
Año de publicación
2022
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
The rate of progression from Mild Cognitive Impairment (MCI) to Alzheimer's disease (AD) is estimated at >10% per year, reaching up to 80–90% after 6 years. MCI is considered an indicator of early-stage AD. In this context, the diagnostic screening of MCI is crucial for detecting individuals at high risk of AD before they progress and manifest further severe symptoms. Typically, MCI has been determined using neuropsychological assessment tools such as the Montreal Cognitive Assessment (MoCA) or Mini-Mental Status Examination (MMSE). Unfortunately, other diagnostic methods are not available or are unable to identify MCI in its early stages. Therefore, identifying new biomarkers for MCI diagnosis and prognosis is a significant challenge. In this framework, miRNAs in serum, plasma, and other body fluids have emerged as a promising source of biomarkers for MCI and AD-related cognitive impairments. Interestingly, miRNAs can regulate several signaling pathways via multiple and diverse targets in response to pathophysiological stimuli. This systematic review aims to describe the current state of the art regarding AD-related target genes modulated by differentially expressed miRNAs in peripheral fluids samples in MCI subjects to identify potential miRNA biomarkers in the early stages of AD. We found 30 articles that described five miRNA expression profiles from peripheral fluid in MCI subjects, showing possible candidates for miRNA biomarkers that may be followed up as fluid biomarkers or therapeutic targets of early-stage AD. However, additional research is needed to validate these miRNAs and characterize the precise neuropathological mechanisms.
Fil: Ogonowski, Natalia Soledad. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Neurociencia Cognitiva. Fundación Favaloro. Instituto de Neurociencia Cognitiva; Argentina. Universidad Adolfo Ibañez; Chile
Fil: Salcidua, Stefanny. Universidad Adolfo Ibañez; Chile
Fil: Leon, Tomas. Universidad de Chile; Chile. Trinity College; Irlanda
Fil: Chamorro Veloso, Nayaret. Neurognos Spa; Chile
Fil: Valls, Cristian. Neurognos Spa; Chile
Fil: Avalos, Constanza. Universidad Adolfo Ibañez; Chile
Fil: Bisquertt, Alejandro. Neurognos Spa; Chile
Fil: Rentería, Miguel E.. Berghofer Medical Research Institute; Australia
Fil: Orellana, Paulina. Universidad Adolfo Ibañez; Chile
Fil: Duran Aniotz, Claudia. Universidad Adolfo Ibañez; Chile
Materia
BIOMARKERS
DIAGNOSIS
FLUID BIOMARKERS
MICRORNA
MILD COGNITIVE IMPAIRMENT
SYSTEMATIC REVIEW
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/213496
Acceder
id CONICETDig_118fd6ef29a712a07180f74d4b29ccad
oai_identifier_str oai:ri.conicet.gov.ar:11336/213496
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Systematic Review: microRNAs as Potential Biomarkers in Mild Cognitive Impairment DiagnosisOgonowski, Natalia SoledadSalcidua, StefannyLeon, TomasChamorro Veloso, NayaretValls, CristianAvalos, ConstanzaBisquertt, AlejandroRentería, Miguel E.Orellana, PaulinaDuran Aniotz, ClaudiaBIOMARKERSDIAGNOSISFLUID BIOMARKERSMICRORNAMILD COGNITIVE IMPAIRMENTSYSTEMATIC REVIEWhttps://purl.org/becyt/ford/3.2https://purl.org/becyt/ford/3The rate of progression from Mild Cognitive Impairment (MCI) to Alzheimer's disease (AD) is estimated at >10% per year, reaching up to 80–90% after 6 years. MCI is considered an indicator of early-stage AD. In this context, the diagnostic screening of MCI is crucial for detecting individuals at high risk of AD before they progress and manifest further severe symptoms. Typically, MCI has been determined using neuropsychological assessment tools such as the Montreal Cognitive Assessment (MoCA) or Mini-Mental Status Examination (MMSE). Unfortunately, other diagnostic methods are not available or are unable to identify MCI in its early stages. Therefore, identifying new biomarkers for MCI diagnosis and prognosis is a significant challenge. In this framework, miRNAs in serum, plasma, and other body fluids have emerged as a promising source of biomarkers for MCI and AD-related cognitive impairments. Interestingly, miRNAs can regulate several signaling pathways via multiple and diverse targets in response to pathophysiological stimuli. This systematic review aims to describe the current state of the art regarding AD-related target genes modulated by differentially expressed miRNAs in peripheral fluids samples in MCI subjects to identify potential miRNA biomarkers in the early stages of AD. We found 30 articles that described five miRNA expression profiles from peripheral fluid in MCI subjects, showing possible candidates for miRNA biomarkers that may be followed up as fluid biomarkers or therapeutic targets of early-stage AD. However, additional research is needed to validate these miRNAs and characterize the precise neuropathological mechanisms.Fil: Ogonowski, Natalia Soledad. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Neurociencia Cognitiva. Fundación Favaloro. Instituto de Neurociencia Cognitiva; Argentina. Universidad Adolfo Ibañez; ChileFil: Salcidua, Stefanny. Universidad Adolfo Ibañez; ChileFil: Leon, Tomas. Universidad de Chile; Chile. Trinity College; IrlandaFil: Chamorro Veloso, Nayaret. Neurognos Spa; ChileFil: Valls, Cristian. Neurognos Spa; ChileFil: Avalos, Constanza. Universidad Adolfo Ibañez; ChileFil: Bisquertt, Alejandro. Neurognos Spa; ChileFil: Rentería, Miguel E.. Berghofer Medical Research Institute; AustraliaFil: Orellana, Paulina. Universidad Adolfo Ibañez; ChileFil: Duran Aniotz, Claudia. Universidad Adolfo Ibañez; ChileFrontiers Media S.A.2022-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/213496Ogonowski, Natalia Soledad; Salcidua, Stefanny; Leon, Tomas; Chamorro Veloso, Nayaret; Valls, Cristian; et al.; Systematic Review: microRNAs as Potential Biomarkers in Mild Cognitive Impairment Diagnosis; Frontiers Media S.A.; Frontiers in Aging Neuroscience; 13; 1-2022; 1-221663-4365CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/https://www.frontiersin.org/articles/10.3389/fnagi.2021.807764/fullinfo:eu-repo/semantics/altIdentifier/doi/10.3389/fnagi.2021.807764info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-29T10:23:31Zoai:ri.conicet.gov.ar:11336/213496instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-29 10:23:31.625CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Systematic Review: microRNAs as Potential Biomarkers in Mild Cognitive Impairment Diagnosis
title Systematic Review: microRNAs as Potential Biomarkers in Mild Cognitive Impairment Diagnosis
spellingShingle Systematic Review: microRNAs as Potential Biomarkers in Mild Cognitive Impairment Diagnosis
Ogonowski, Natalia Soledad
BIOMARKERS
DIAGNOSIS
FLUID BIOMARKERS
MICRORNA
MILD COGNITIVE IMPAIRMENT
SYSTEMATIC REVIEW
title_short Systematic Review: microRNAs as Potential Biomarkers in Mild Cognitive Impairment Diagnosis
title_full Systematic Review: microRNAs as Potential Biomarkers in Mild Cognitive Impairment Diagnosis
title_fullStr Systematic Review: microRNAs as Potential Biomarkers in Mild Cognitive Impairment Diagnosis
title_full_unstemmed Systematic Review: microRNAs as Potential Biomarkers in Mild Cognitive Impairment Diagnosis
title_sort Systematic Review: microRNAs as Potential Biomarkers in Mild Cognitive Impairment Diagnosis
dc.creator.none.fl_str_mv Ogonowski, Natalia Soledad
Salcidua, Stefanny
Leon, Tomas
Chamorro Veloso, Nayaret
Valls, Cristian
Avalos, Constanza
Bisquertt, Alejandro
Rentería, Miguel E.
Orellana, Paulina
Duran Aniotz, Claudia
author Ogonowski, Natalia Soledad
author_facet Ogonowski, Natalia Soledad
Salcidua, Stefanny
Leon, Tomas
Chamorro Veloso, Nayaret
Valls, Cristian
Avalos, Constanza
Bisquertt, Alejandro
Rentería, Miguel E.
Orellana, Paulina
Duran Aniotz, Claudia
author_role author
author2 Salcidua, Stefanny
Leon, Tomas
Chamorro Veloso, Nayaret
Valls, Cristian
Avalos, Constanza
Bisquertt, Alejandro
Rentería, Miguel E.
Orellana, Paulina
Duran Aniotz, Claudia
author2_role author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv BIOMARKERS
DIAGNOSIS
FLUID BIOMARKERS
MICRORNA
MILD COGNITIVE IMPAIRMENT
SYSTEMATIC REVIEW
topic BIOMARKERS
DIAGNOSIS
FLUID BIOMARKERS
MICRORNA
MILD COGNITIVE IMPAIRMENT
SYSTEMATIC REVIEW
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.2
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv The rate of progression from Mild Cognitive Impairment (MCI) to Alzheimer's disease (AD) is estimated at >10% per year, reaching up to 80–90% after 6 years. MCI is considered an indicator of early-stage AD. In this context, the diagnostic screening of MCI is crucial for detecting individuals at high risk of AD before they progress and manifest further severe symptoms. Typically, MCI has been determined using neuropsychological assessment tools such as the Montreal Cognitive Assessment (MoCA) or Mini-Mental Status Examination (MMSE). Unfortunately, other diagnostic methods are not available or are unable to identify MCI in its early stages. Therefore, identifying new biomarkers for MCI diagnosis and prognosis is a significant challenge. In this framework, miRNAs in serum, plasma, and other body fluids have emerged as a promising source of biomarkers for MCI and AD-related cognitive impairments. Interestingly, miRNAs can regulate several signaling pathways via multiple and diverse targets in response to pathophysiological stimuli. This systematic review aims to describe the current state of the art regarding AD-related target genes modulated by differentially expressed miRNAs in peripheral fluids samples in MCI subjects to identify potential miRNA biomarkers in the early stages of AD. We found 30 articles that described five miRNA expression profiles from peripheral fluid in MCI subjects, showing possible candidates for miRNA biomarkers that may be followed up as fluid biomarkers or therapeutic targets of early-stage AD. However, additional research is needed to validate these miRNAs and characterize the precise neuropathological mechanisms.
Fil: Ogonowski, Natalia Soledad. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Neurociencia Cognitiva. Fundación Favaloro. Instituto de Neurociencia Cognitiva; Argentina. Universidad Adolfo Ibañez; Chile
Fil: Salcidua, Stefanny. Universidad Adolfo Ibañez; Chile
Fil: Leon, Tomas. Universidad de Chile; Chile. Trinity College; Irlanda
Fil: Chamorro Veloso, Nayaret. Neurognos Spa; Chile
Fil: Valls, Cristian. Neurognos Spa; Chile
Fil: Avalos, Constanza. Universidad Adolfo Ibañez; Chile
Fil: Bisquertt, Alejandro. Neurognos Spa; Chile
Fil: Rentería, Miguel E.. Berghofer Medical Research Institute; Australia
Fil: Orellana, Paulina. Universidad Adolfo Ibañez; Chile
Fil: Duran Aniotz, Claudia. Universidad Adolfo Ibañez; Chile
description The rate of progression from Mild Cognitive Impairment (MCI) to Alzheimer's disease (AD) is estimated at >10% per year, reaching up to 80–90% after 6 years. MCI is considered an indicator of early-stage AD. In this context, the diagnostic screening of MCI is crucial for detecting individuals at high risk of AD before they progress and manifest further severe symptoms. Typically, MCI has been determined using neuropsychological assessment tools such as the Montreal Cognitive Assessment (MoCA) or Mini-Mental Status Examination (MMSE). Unfortunately, other diagnostic methods are not available or are unable to identify MCI in its early stages. Therefore, identifying new biomarkers for MCI diagnosis and prognosis is a significant challenge. In this framework, miRNAs in serum, plasma, and other body fluids have emerged as a promising source of biomarkers for MCI and AD-related cognitive impairments. Interestingly, miRNAs can regulate several signaling pathways via multiple and diverse targets in response to pathophysiological stimuli. This systematic review aims to describe the current state of the art regarding AD-related target genes modulated by differentially expressed miRNAs in peripheral fluids samples in MCI subjects to identify potential miRNA biomarkers in the early stages of AD. We found 30 articles that described five miRNA expression profiles from peripheral fluid in MCI subjects, showing possible candidates for miRNA biomarkers that may be followed up as fluid biomarkers or therapeutic targets of early-stage AD. However, additional research is needed to validate these miRNAs and characterize the precise neuropathological mechanisms.
publishDate 2022
dc.date.none.fl_str_mv 2022-01
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/213496
Ogonowski, Natalia Soledad; Salcidua, Stefanny; Leon, Tomas; Chamorro Veloso, Nayaret; Valls, Cristian; et al.; Systematic Review: microRNAs as Potential Biomarkers in Mild Cognitive Impairment Diagnosis; Frontiers Media S.A.; Frontiers in Aging Neuroscience; 13; 1-2022; 1-22
1663-4365
CONICET Digital
CONICET
url http://hdl.handle.net/11336/213496
identifier_str_mv Ogonowski, Natalia Soledad; Salcidua, Stefanny; Leon, Tomas; Chamorro Veloso, Nayaret; Valls, Cristian; et al.; Systematic Review: microRNAs as Potential Biomarkers in Mild Cognitive Impairment Diagnosis; Frontiers Media S.A.; Frontiers in Aging Neuroscience; 13; 1-2022; 1-22
1663-4365
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/url/https://www.frontiersin.org/articles/10.3389/fnagi.2021.807764/full
info:eu-repo/semantics/altIdentifier/doi/10.3389/fnagi.2021.807764
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Frontiers Media S.A.
publisher.none.fl_str_mv Frontiers Media S.A.
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1844614230147334144
score 13.070432

Publicaciones similares